SWE Liver Stiffness as a Predictor of Progression of Chronic Liver Diseases (SWE Predict)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03389152
Recruitment Status : Enrolling by invitation
First Posted : January 3, 2018
Last Update Posted : December 19, 2018
University of Bonn
Information provided by (Responsible Party):
SuperSonic Imagine

Brief Summary:
This study is a multicenter individual patient-based meta-analysis that will assess the performances of liver stiffness measurements performed with supersonic shear imaging shearwave elastography (SSI-SWE) in patients with liver fibrosis to predict progression of chronic liver disease.

Condition or disease Intervention/treatment
Liver Fibroses Device: Elastography

Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Evaluation of SWE as a Predictive Tool for Progression of Chronic Liver Diseases
Actual Study Start Date : February 1, 2010
Actual Primary Completion Date : November 28, 2018
Estimated Study Completion Date : November 28, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases

Intervention Details:
  • Device: Elastography
    liver stiffness measurements by shear wave-based elastography

Primary Outcome Measures :
  1. Liver disease progression rate [ Time Frame: Minimum of 1 year follow-up ]
    Clinical signs of liver decompensation

  2. Mortality rate [ Time Frame: Minimum of 1 year follow-up ]
    Patient's death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with suspected or confirmed chronic liver disease of viral and/or steatotic origin, requiring a percutaneous liver biopsy, and who had received a liver ultrasound exam at baseline for a suspected chronic fibrotic liver disease.

Inclusion Criteria:

  • Patients who had received a liver ultrasound exam at baseline for a suspected chronic fibrotic liver disease of viral and/or steatotic origin,
  • Patients who had reached the age of majority in their countries, at baseline,
  • Patients with a baseline liver biopsy for histological evaluation of liver fibrosis with a length ≥ 15 mm paraffin sections (except if cirrhosis),
  • Patients for whom a minimum length of clinical follow-up from baseline of 1 year had been recorded

Exclusion Criteria:

  • Cause of chronic liver disease other than viral, ALD or NAFLD ( hemochromatosis, autoimmune hepatitis, biliary tract disease intrahepatic...)
  • Any systemic, viral hepatitis and HIV co-infection

Responsible Party: SuperSonic Imagine Identifier: NCT03389152     History of Changes
Other Study ID Numbers: LE3
First Posted: January 3, 2018    Key Record Dates
Last Update Posted: December 19, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: At the end of the study, sharing of IPD will not be required.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Liver Diseases
Liver Cirrhosis
Digestive System Diseases